Pfizer unveils new $1b manufacturing facility in Tuas Biomedical Park

The facility spans 429,000 sq ft.

Pfizer has launched its $1b Active Pharmaceutical Ingredient (API) manufacturing facility in Tuas Biomedical Park.

The facility spans 429,000 sq ft and will produce small molecule APIs for Pfizer’s oncology, pain, and antibiotic medicines globally. The expansion will also create over 250 jobs.

Construction began in 2020 and was designed to accommodate future additions such as processing suites, dry-end suites, dispensaries, a warehouse, and ancillary equipment. 

Design priorities included integrating systems and technologies to increase energy efficiency and manage energy demand effectively. The facility also holds a Green Mark Gold certification.